BANK VONTOBEL/CALL/BIOGEN IDEC/310/0.01/20.09.24 | Delayed Deutsche Boerse AG 02:01:32 2024-07-08 pm EDT | ||
| 0.002 EUR | +100.00% |
|
| Current month | -33.33% | ||
| 1 month | -75.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-08 | 0.002 | +100.00% |
| 24-07-05 | 0.001 | -50.00% |
| 24-07-04 | 0.002 | 0.00% |
| 24-07-03 | 0.002 | -33.33% |
| 24-07-02 | 0.003 | -25.00% |
Delayed Quote Deutsche Boerse AG
Last update July 08, 2024 at 02:01 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VM3MVT |
| ISIN | DE000VM3MVT3 |
| Date issued | 2023-10-06 |
| Strike | 310 $ |
| Maturity | 2024-09-20 (74 Days) |
| Parity | 100 : 1 |
| Emission price | 0.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.26 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.017 € |
| Spread % | 85.00% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
228.1
USD
Average target price
283.2
USD
Spread / Average Target
+24.15%
- Stock Market
- Warrants
- Warrant
